Related Experiment Video
Updated: Jul 2, 2026

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
Published on: October 3, 2018
Myelodysplastic syndrome
V Tilak1, D D Sookmane, V Gupta
1Department of Pathology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India. vijaitilak@rediffmail.com
Abstract:
Pediatric myelodysplastic syndrome (MDS), though rare, constitutes a distinct entity quite different from adult MDS. They have unique clinical features, aggressive clinical course with an overall mean survival of only 9.9 months. A pediatric approach to the WHO classification has become necessary since the WHO classification of MDS has failed to address the uniqueness of pediatric MDS. A new prognostic system also needs to be evolved since the international prognostic system has limited prognostic impact in children. Intensive chemotherapy such as the one used in de novo-acute myeloid leukemia (AML) leads to complete remission in some children and this may be the treatment of choice in pediatric MDS.
Related Concept Videos
Satellite Stem Cells and Muscular Dystrophy
Cellular Adaptation IV: Dysplasia and Metaplasia
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy II: Dilated Cardiomyopathy
Multiple Sclerosis l: Introduction
Abnormal Proliferation

